Scarica l'app Stockscreener
4.89
1.61%
-0.08
Dopo l'orario di chiusura:
4.80
-0.09
-1.84%
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica (VRCA) Q2 2026 Earnings Call Transcript - AOL.com
Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen - marketbeat.com
Verrica Revenue Falls Despite Record YCANTH Demand - MyChesCo
Verrica Pharmaceuticals Inc. R (1NE0.DU) balance sheet - Yahoo Finance UK
Q2 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Verrica Pharmaceuticals Inc. R (1NE0.DU) stock price, news, quote and history - Yahoo Finance UK
Verrica Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Verrica secures $27.5 million credit facility from chairman By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals (NASDAQ:VRCA) Releases Earnings Results - MarketBeat
Earnings call transcript: Verrica Q2 2026 loss widens as YCANTH sales rise - Investing.com
Verrica Pharmaceuticals earnings missed by $0.08, revenue topped estimates - Investing.com Canada
Verrica Q2 2026 Earnings: YCANTH Growth Was Masked by a Milestone Comparison - TradingKey
Is Verrica Pharmaceuticals (VRCA) a Hidden Gem After Q2 Earnings - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Verrica Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Verrica Pharmaceuticals Inc. 2026: Revenue $5.86M, EPS ($0.62) — 10-Q Summary - TradingView
Verrica secures $27.5 million credit facility from chairman - Investing.com
Verrica Reports Q2 Revenue of $5.9 Million as YCANTH Demand Rises - Quiver Quantitative
Verrica Pharmaceuticals reports Q2 2026 revenue $5.9M, net loss $13.2M; YCANTH demand up - TradingView
Verrica Pharmaceuticals Inc. (VRCA) Q2 FY2026 earnings call transcript - Yahoo Finance
Verrica Pharma reports wider-than-expected Q2 adj loss per share - TradingView
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results - manilatimes.net
YCANTH applicator units reach 19,626; common-wart data expected mid-2027 - Stock Titan
Press Release: Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - Moomoo
Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital - GlobeNewswire
Verrica Schedules Aug. 6 Earnings Call With Corporate Update - MyChesCo
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Verrica Pharmaceuticals Inc. R (1NE0.DU) Options Chain - Yahoo! Finance Canada
Graphique interactif des capital-actions 1NE0.SG| Capital-actions Verrica Pharmaceuticals Inc. - Yahoo Finance France
Verrica Pharmaceuticals (VRCA) Projected to Release Quarterly Earnings on Thursday - marketbeat.com
Verrica Pharmaceuticals to Report Second Quarter 2026 - GlobeNewswire
Verrica Sets Aug. 6 Webcast to Discuss Second-Quarter Results - Stock Titan
Verrica Pharmaceuticals (VRCA) Slips Over 4% as Shares Test Near-Term Support at $4.92Dark Pool Prints - dars.gov.et
Verrica Expands YCANTH Rights to Israel in Licensing Deal - MyChesCo
VRCA|Verrica Pharmaceuticals Inc|Price:4.935|Chg%:+0.075 - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRCA|Verrica Pharmaceuticals Inc|Price:5.020|Chg%:-0.420 - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
TradingKey - TradingKey
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com - Investing.com Nigeria
Verrica grants Medomie exclusive rights for YCANTH in Israel - Investing.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - The Manila Times
Verrica deal could bring YCANTH to Israeli children if approved - Stock Titan
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds FirmFibonacci Arc - dars.gov.et
Verrica Pharmaceuticals holds the spotlight after recent market context - ad-hoc-news.de
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
VRCAVerrica Pharmaceuticals Inc Latest SEC Filings - Finviz
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals (VRCA) Rises 2% as Shares Test Resistance Near $6.36Factor Momentum - dars.gov.et
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell 3000E Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Price to book forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0 - TradingView
1.80%
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):